Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Melanie Pronk"'
Autor:
Juliane Weilandt, Katharina Diehl, Marthe Lisa Schaarschmidt, Felix Kieker, Bianca Sasama, Melanie Pronk, Jan Ohletz, Andreas Könnecke, Verena Müller, Jochen Utikal, Uwe Hillen, Wolfgang Harth, Wiebke K. Peitsch
Publikováno v:
Acta Dermato-Venereologica, Vol 100, Iss 6, p adv00083 (2020)
Treatment paradigms for advanced melanoma have changed fundamentally over recent years. A discrete choice experiment was performed to explore patient preferences regarding outcome (overall response rate, 2-year survival rate, progression-free surviva
Externí odkaz:
https://doaj.org/article/0cc08fefb2474e88985559a7505e4caf
Autor:
Uwe Hillen, Jochen Utikal, Bianca Sasama, Wolfgang Harth, Verena Müller, Jan Ohletz, Melanie Pronk, Wiebke K. Peitsch, Andreas Könnecke, Felix Kiecker, Katharina Diehl, Juliane Weilandt, Marthe-Lisa Schaarschmidt
Publikováno v:
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 19:58-72
Autor:
Melanie Pronk, Jan Ohletz, Wolfgang Harth, Andreas Könnecke, Marthe-Lisa Schaarschmidt, Jochen Utikal, Juliane Weilandt, Katharina Diehl, Verena Müller, Bianca Sasama, Wiebke K. Peitsch, Felix Kiecker, Uwe Hillen
Publikováno v:
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGReferences. 19(1)
Background and objectives Choice of treatment for advanced melanoma is crucially influenced by comorbidities and patient preferences. Our study aimed to investigate the impact of comorbidities on preferences. Patients and methods 150 patients with me
Autor:
Wolfgang Harth, Bianca Sasama, Verena Müller, Uwe Hillen, Jan Ohletz, Wiebke K. Peitsch, Felix Kieker, Marthe Lisa Schaarschmidt, Juliane Weilandt, Andreas Könnecke, Jochen Utikal, Melanie Pronk, Katharina Diehl
Publikováno v:
Acta Dermato-Venereologica, Vol 100, Iss 6, p adv00083 (2020)
Treatment paradigms for advanced melanoma have changed fundamentally over recent years. A discrete choice experiment was performed to explore patient preferences regarding outcome (overall response rate, 2-year survival rate, progression-free surviva